Retatrutide vs Tirzepatide: a New Zealand researcher's guide
Retatrutide and tirzepatide are two of the most discussed incretin-modulating peptides in the current research literature. Both are supplied in New Zealand strictly for in-vitro laboratory use. This guide compares their mechanism, format, handling and sourcing so NZ researchers can plan studies with the right compound.
Mechanism at a glance
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GIP + GLP-1 (dual agonist) | GIP + GLP-1 + Glucagon (triple agonist) |
| Format supplied | Lyophilised powder, vial | Lyophilised powder, vial |
| Typical research strength | 5–15 mg / vial | 10–20 mg / vial |
| Reconstitution | Bacteriostatic water, aseptic | Bacteriostatic water, aseptic |
| Storage | 2–8 °C, protect from light | 2–8 °C, protect from light |
| NZ regulatory status | Unapproved — research use only | Unapproved — research use only |
Why the third receptor matters
Tirzepatide's dual GIP/GLP-1 mechanism drives insulinotropic and satiety pathways. Retatrutide adds glucagon receptor agonism, which in published Phase 2 research has been associated with additional energy-expenditure and lipolytic activity. The trade-off is a mechanism that researchers are still characterising — fewer long-term datasets exist for retatrutide than for tirzepatide.
Handling considerations in NZ
- Use a fresh vial of bacteriostatic water per reconstitution. Avoid sharing diluent across vials.
- Draw with low-dead-space insulin syringes to preserve dose accuracy at small volumes.
- Transport reconstituted aliquots in an insulated case such as the Vantara safety case to maintain the cold chain between bench and storage.
- Document batch numbers and the date of reconstitution — both compounds degrade once in solution.
Sourcing in New Zealand
Vantara stocks both retatrutide and tirzepatide at our Auckland facility. Orders ship same-day on weekdays before 1pm NZT with tracked courier nationwide. Every batch is independently tested by HPLC and mass spectrometry — a Certificate of Analysis is available on request before purchase. Browse the full peptide range or read our NZ peptide overview.
Start your research order
Browse retatrutide, tirzepatide and the full Vantara peptide range — all tested and shipped from Auckland.
Frequently asked questions
What is the difference between retatrutide and tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide is a triple agonist — it activates GIP, GLP-1 and the glucagon receptor. The added glucagon agonism is the headline mechanistic difference being studied.
Is retatrutide stronger than tirzepatide in research data?
Published Phase 2 research on retatrutide reports larger mean body-weight reductions than the corresponding tirzepatide trials, but the two compounds have not been compared head-to-head in a single trial, so direct potency claims are not yet supported.
Are retatrutide and tirzepatide legal to purchase in New Zealand?
Both are unapproved compounds in New Zealand and are supplied strictly for in-vitro laboratory research only. They are not medicines and are not intended for human or veterinary use.
How should retatrutide and tirzepatide be stored?
Lyophilised vials are stable at 2–8 °C, protected from light. Once reconstituted with bacteriostatic water, refrigerate and use within the stability window defined by your validated protocol.
Where can NZ researchers source retatrutide and tirzepatide?
Vantara stocks both compounds in Auckland and ships tracked nationwide. Every batch is third-party tested by HPLC and mass spectrometry, with a Certificate of Analysis available on request.